<DOC>
	<DOCNO>NCT00440544</DOCNO>
	<brief_summary>The purpose study determine whether subunit tuberculosis vaccine give two nasal immunization compose hybrid protein antigen M. tuberculosis virus mixed toxoid adjuvant , cause untoward adverse reaction administer healthy adult volunteer . Both subject receive Bacillus Calmette-Guerin ( BCG ) subject already receive BCG enrol . An initial evaluation immune response vaccine also undertaken .</brief_summary>
	<brief_title>A Phase I Trial LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine ( Ag85B-ESAT6 )</brief_title>
	<detailed_description>The purpose study determine whether subunit tuberculosis vaccine give two nasal immunization compose hybrid protein antigen M. tuberculosis virus mixed toxoid adjuvant , cause untoward adverse reaction administer healthy adult volunteer . Both subject receive BCG subject already receive BCG enrol . An initial evaluation immune response vaccine also undertaken use flow cytometry enumerate antigen specific IFNg contain T cell ; ELISPOT determine IFNg secrete antigen specific T cell ; serology nasal wash antibody .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Signed informed consent Healthy , base medical examination inclusion Male female subject , age 18 55 year Willing likely able comply trial procedure Prepared grant authorize person access medical record Additional inclusion criterion BCGnonvaccinated subject : BCGnonvaccinated ( i.e. , absence BCGscar ) Negative Mantoux skin test Additional inclusion criterion BCGvaccinated subject : BCGvaccinated ( i.e. , presence BCGscar ) History TB know exposure TB Radiological finding chest X ray compatible previous current infection tuberculosis Positive QuantiFERONÂ® TBGold test Evidence previous , current latent tuberculosis Evidence previous , current latent tuberculosis History severe organsystem disease Known hypersensitivity vaccine component History allergic disorder Vaccinated vaccine within 3 month first vaccination Congenital and/or acquire immune disease Administration systemic immune modulating drug ( steroid , immunosuppressive drug immunoglobulin ) within 3 month first vaccination ( topical steroid include ) Autoimmune diseases HIV , HBV HCV seropositive Established diagnosis neurological neuromuscular disease , specifically history abnormality respect sense smell ( olfactory nerve dysfunction ) , previous current facial nerve paralysis Congenital acquire abnormality disorder related nasal nasopharyngeal cavity Current use medication take nasal/inhalatory route include cocaine drug Laboratory parameter outside normal range consider clinically significant Pregnant accord urine pregnancy test Females willing use contraceptive breastfeed Intake trial medication clinical trial within 6 month first vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>vaccine</keyword>
	<keyword>nasal immunization</keyword>
</DOC>